New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
08:20 EDTOCLSOculus announces issuance of U.S. patent for treatment of skin ulcers
Oculus announced the issuance of new U.S. patent for the use of Microcyn Technology in the treatment of skin ulcers. In this application, Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the Microcyn Technology.
News For OCLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
14:46 EDTOCLSOculus to host special shareholder meeting
Special shareholder meeting to be held in Petaluma, California on June 29 at 1 pm.
07:25 EDTOCLSOculus coverage assumed with a Buy at Maxim
Subscribe for More Information
June 18, 2015
06:01 EDTOCLSOculus regains compliance with NASDAQ minimum price listing rule
Subscribe for More Information
June 16, 2015
06:07 EDTOCLSOculus announces sale of 1.65M shares of Ruthigen stock for $4.5M
Oculus (OCLS) announced the sale of its remaining 1.65M shares of Ruthigen (RTGN) stock to an investor group at $2.75 per share for non-dilutive funding of $4.5M. The sale is expected to close three days after the consummation of the merger between Ruthigen and Pulmatrix, a clinical-stage biotechnology company. This merger was approved by Ruthigen and Pulmatrix shareholders on June 12, 2015, and consummated on June 15, 2015. The final transfer of the Ruthigen shares and funds is expected to be completed on or before June 18, 2015. With completion of the merger, Oculus' management anticipates one of three outcomes relative to these milestones and royalties: Ruthigen/Pulmatrix will continue to move the clinical study forward and be responsible for future milestone and royalty payments; Ruthigen/Pulmatrix would sell these licensing rights to another company, which would then be accountable to Oculus for the same milestone payments and royalties. Ruthigen/Pulmatrix has until August 31, 2016, to complete the sale or initiate the clinical program; Or If neither of the above alternatives are completed and/or initiated, then the drug formulations license will revert back to Oculus.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use